MaxCyte and Imugene, page-30

I wouldn't expect an announcement from IMU for this agreement as MaxCyte was a partner of Precision Biosciences and their platform was already part of the Azer-cel production process.

Here's a December 2023 Corporate Presentation from MaxCyte for anyone interested: PowerPoint Presentation (maxcyte.com)


Signing this agreement is almost certainly part and parcel of the transfer of the Azer-cel manufacturing facility to IMU and whilst it is important for this agreement to have been signed (something else Monil Shah is likely to have negotiated), it is somewhat equivalent to changing over the electricity and water. i.e. to be expected and necessary to continue operations but not really something new.

However, for MaxCyte, the announcement is almost certainly worthwhile to highlight that IMU is planning to push Azer-cel into a Ph2 registrational trial and they will generate income off the back of a successful registration by way of platform licensing fees and program-related revenue.